Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help...
Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven po...
Pfizer Inc. (NYSE:PFE) is one of the stocks that Jim Cramer weighed in on. A caller asked if they sh...
PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lac...
PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and ...